• Open Access

Matrix metalloproteinase-1 contribution to sarcoma cell invasion

Authors

  • Nandor Garamszegi,

    Corresponding author
    1. Sarcoma Biology Laboratory of Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, FL, USA
    2. NAG-Biosystems, FL, USA
    Search for more papers by this author
  • Susanna P. Garamszegi,

    1. Department of Neurology, University of Miami, Miller School of Medicine, FL, USA
    Search for more papers by this author
  • Sean P. Scully

    1. Sarcoma Biology Laboratory of Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, FL, USA
    2. Department of Orthopaedics at University of Miami, Miller School of Medicine, FL, USA
    Search for more papers by this author

Present address: 9100 S Dadeland Blvd., STE 1500 Miami, FL 33156, USA.

Nandor GARAMSZEGI, University of Miami, Miller School of Medicine, M877 Papanicolau Building Room 315, 1550 N.W. 10th Avenue, Miami, FL 33136, USA. Tel.: 305-243-6329 Fax: 305-243-9445 E-mail: ngaramszegi@med.miami.edu, sunag101@gmail.com

Abstract

Matrix metalloproteinase-1 (MMP-1) activity has been linked to numerous disease processes from arthritis to ulcer. Its proteolytic activity has been implicated inconsistently in different steps of tumourigenesis and metastasis. The discrepancies may be attributable to our limited understanding of MMP-1 production, cellular trafficking, secretion and local activation. Specifically, regulation of MMP-1 directional delivery versus its general extracellular matrix secretion is largely unknown. Inhibition of prenylation by farnesyl transferase inhibitor (FTI-276) decreased extracellular MMP-1 and subsequently reduced invasiveness by 30%. Parallel, stable cell line RNAi knockdown of MMP-1 confirmed its role in cellular invasiveness. The prenylation agonist farnesyl pyrophosphate (FPP) partially normalized FTI-276 inhibited extracellular MMP-1 levels and invasion capacity while transiently delayed its cellular podia distribution. MMP-1 directional delivery to these structures were confirmed by combination of a MMP-1–specific fluorogenic substrate, a MMP1-Ds-Red fusion protein construct expression and DQ-collagen degradation, which demonstrated coupling of directional delivery and activation. MetaMorph analysis of cellular lamellipodia structures indicated that FTI-276 inhibited formation and delivery to these structures. Farnesyl pyrophosphate partially restored lamellipodia area but not MMP-1 delivery under the time frame investigated. These results indicate that MMP-1 directional delivery to podia structures is involved in the invasive activity of sarcoma cells, and this process is prenylation sensitive.

Ancillary